UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

Pharmacogenomics Journal

Volumn 2, Issue 1, 2002, Pages 43-47

  Iyer, L ^a   Das, S ^a   Janisch, L ^a   Wen, M ^a   Ramirez J ^a   Karrison, T ^a   Fleming, G F ^a   Vokes, E E ^a   Schilsky, R L ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Glucuronidation; Irinotecan; Polymorphism; SN 38; UGT1A1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ADENOSINE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; LOPERAMIDE; ONDANSETRON; THYMINE; 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PHENOL GLUCURONOSYLTRANSFERASE;

ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG ACTIVATION; DRUG DETOXIFICATION; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG INFUSION; DRUG METABOLISM; DRUG TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; IN VITRO STUDY; MALE; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; ALLELE; GENETIC POLYMORPHISM; GENETICS;

ADULT; ALLELES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; POLYMORPHISM, GENETIC;

EID: 0036025450     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500072     Document Type: Article

References (23)

1. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
2. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
3. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
4. Congenital familial nonhemolytic jaundice with kernicterus
5. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
6. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
7. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
8. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome
9. Variability at the uridine diphosphate glucuronosyltransferase 1Al promoter in human populations and primates
10. Study on the mechanisms of diarrhea induced by the new anticancer drug irinotecan hydrochloride (CPT-11)
11. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients
12. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports
13. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
14. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
15. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
16. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese
17. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese
18. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: A common missense mutation among Japanese, Koreans and Chinese
19. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
20. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
21. Role of p-glycoprotein (Pgp) in biliary excretion of irinotecan (CPT-11) in normal and mdr1a/1b(-/-) mice
22. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy
23. A Wilcoxon-type test for trend